In conclusion, we establish our initial proof-of-concept that a small molecule NMT inhibitor, PCLX-001, potently and selectively inhibits the growth of a wide spectrum of cultured cancer cells in vitro, with particularly pronounced effects in cells derived from hematologic cancers including B-cell lymphoma due to the loss of BCR-mediated signaling events, their main source of pro-survival signals4–8. The gene discussed is NMT1; the disease is B-cell non-Hodgkin lymphoma.